"P53 is mutated in around 70% of all cancers and is therefore an attractive target for therapy, yet despite many years of research, it has proven difficult for researchers to develop drugs to.  Part of the problem is there are many different mutations that affect this master regulator of cell survival.  This paper presents promising results from an early phase clinical trial using a new drug, Rezatapopt, which targets one particular mutation.  The trial showed 20% of patients had a response (at least 30% tumour shrinkage), and in a wide range of cancer types.

These results are highly impressive for such an early stage of trial in patients who had all undergone many different therapies before entering this trial. These are the most resistant and difficult cases, as their cancers were highly advanced.

This approach is attractive as Rezatapopt would be able to treat many different cancer types, and it can be taken orally, so it could be taken at home.

It offers a hope that we might finally have at least a partial solution to targeting the most important protein in cancer.

A larger trial is underway that will test if treatment will cure patients of their cancer."